GLENMARK Intraday Analysis...

GLENMARK Share Price

Open 585.00 Change Price %
High 596.00 1 Day 9.80 1.68
Low 584.10 1 Week 15.55 2.70
Close 592.50 1 Month -16.05 -2.64
Volume 696523 1 Year -308.90 -34.27
52 Week High 972.95
52 Week Low 567.80
GLENMARK Important Levels
Resistance 2 603.53
Resistance 1 598.99
Pivot 590.87
Support 1 586.01
Support 2 581.47
NSE INDIA Most Active Stocks
RCOM 12.05 -0.41%
RTNPOWER 8.80 15.79%
JPASSOCIAT 18.75 0.54%
IDEA 101.10 6.20%
SOUTHBANK 31.45 2.95%
SUZLON 13.60 -0.73%
HDIL 64.45 0.78%
TATAPOWER 91.70 3.09%
IBREALEST 233.05 7.52%
SAIL 81.45 3.49%
More..
NSE INDIA Top Gainers Stocks
RAJRAYON 0.25 25.00%
SKMEGGPROD 97.80 20.00%
PROVOGE 6.90 20.00%
STERTOOLS 380.60 19.99%
PKTEA 275.85 19.99%
JAICORPLTD 142.10 19.97%
ORTINLABSS 20.15 19.94%
VIKASECO 26.55 19.86%
CELESTIAL 20.60 19.77%
DIGJAMLTD 14.60 19.67%
More..
NSE INDIA Top Losers Stocks
SPCENET 0.15 -25.00%
KSERASERA 0.15 -25.00%
SUNDARAM 3.50 -16.67%
MIRCELECTR 34.05 -7.85%
XCHANGING 58.45 -6.78%
PDMJEPAPER 27.00 -6.41%
ANTGRAPHIC 0.80 -5.88%
ALCHEM 15.70 -5.42%
SURANASOL 21.15 -5.16%
JKCEMENT 1025.75 -5.11%
More..

Glenmark Pharmaceuticals Limited (NSE: GLENMARK)

GLENMARK Technical Analysis 4
As on 20th Nov 2017 GLENMARK Share Price closed @ 592.50 and we RECOMMEND Strong Sell for LONG-TERM with Stoploss of 749.17 & Sell for SHORT-TERM with Stoploss of 603.44 we also expect STOCK to react on Following IMPORTANT LEVELS.
GLENMARK Target for November
1st Target up-side 635.28
2nd Target up-side 647.6
3rd Target up-side 659.92
1st Target down-side 600.12
2nd Target down-side 587.8
3rd Target down-side 575.48
GLENMARK Synopsis Technicals View
50 Day EMA Close is Below EMA 50 (Short Term)
Bearish
100 Day EMA Close is Below EMA 100 (Mid Term) Bearish
200 Day EMA Close is Below EMA 200 (Long Term) Bearish
MACD (12 26 9) MACD Line is Less Then SIGNAL Line Bearish
RSI (14) RSI is 45.73 Sideways
MFI (14) MFI is 45.41 Sideways
CCI (20) CCI is -58.24 Sideways
WILLIAM %R (14) William %R is -78.26 Sideways
ADX (14) ADX is 14.60 Range Bound
PSAR Stoploss For Short Sell 616.38
10 Day Avg Volume Traded -15.42 % Less then 10 Day Average Volume
GLENMARK Other Details
Segment EQ
Market Capital 68178259968.00
Sector Healthcare
Industry Drugs - Generic
Offical website http://www.glenmarkpharma.com
GLENMARK Address
GLENMARK
Glenmark House
B D S Marg
Mumbai, 400099
India
Phone: 91 22 4018 9999
Fax: 91 22 4018 9990
GLENMARK Latest News
Interactive Technical Analysis Chart Glenmark Pharmaceuticals Limited ( GLENMARK NSE INDIA )
Java support must be enabled in order to display FnCharts.
You can download Java from http://www.java.com
Your Comments and Response on Glenmark Pharmaceuticals Limited
GLENMARK Business Profile
Glenmark Pharmaceuticals (GPL) is engaged in the research and development, manufacturing and marketing of branded formulations in India and abroad. The company is headquartered at Mumbai and was incorporated in the year 1977 by Gracias Saldanha. Its business segments include India API, exports formulations and API NCE research. The company is present in over 80 countries across the globe, with some of its subsidiaries and representative offices in the United States, the United Kingdom, Switzerland, Brazil, South Africa, Nigeria, Russia, Philippines and Malaysia. It has been involved in new drug discoveries such as new molecules for asthma, obesity and diabetes segments. Glenmark has been involved in API business. Glenmark conducts its operations through its manufacturing plants including Baddi, Goa, Nasik and Sao Paulo, Brazil for formulations and Ankleshwar, Kurkumbh and Solapur for API. Glenmark Pharmaceuticals` research activities encompass process engineering for APIs, new chemical entity research and novel drug delivery systems [NDDS]. The company also operates a second research facility at Sinnar, India that focuses on developing formulations for India and markets across Asia, Africa, Latin America and CIS/Russia. The company is further researching PDE-4 inhibitors for CNS indications, cognitive disorders and inflammatory conditions such as atopic dermatitis, ulcerative colitis and rheumatoid arthritis. Other research areas include diabetes segment in which the company has a DPP-IV target, GRC 8200, in Phase I clinical trials. For the last five years the company has increased its growth through investment in dedicated research and development, including cutting-edge New Chemical Technology (NCE) research. The company currently ranks among the top 20 Indian pharmaceutical firms. The current market capitalization stands at Rs 13,855.67 crore. The company has reported a consolidated sales of Rs 1463.38 crore and a Net Profit of Rs 157.3 crore for the quarter ended September 2013. The company management includes Glenn Saldanha - Chairman & Managing Director, Rajesh V Desai - Executive Director & CFO, Cherylann Pinto - Director - Corporate Affairs, D R Mehta - Non Executive Director, Bernard Munos - Non Executive Director, J F Ribeiro - Non Executive Director, Brian W Tempest - Non Executive Director, Sridhar Gorthi - Non Executive Director, Hocine Sidi Said - Non Executive Director, N B Desai - Non Executive Director. The Registered office is at B/2, Mahalaxmi Chambers, 22, Bhulabhai Desai Road, Mumbai,Maharashtra - 400026 and corporate office is at Glenmark House, HDO Corporate Building, Wing - A, B. D. Sawant Marg, Chakala, Off Western Express Highway, Andheri - E, Mumbai - 400099 in MAHARASHTRA.